Related references
Note: Only part of the references are listed.Functional heterogeneity of alveolar macrophage population based on expression of CXCL2
Shengjie Xu-Vanpala et al.
SCIENCE IMMUNOLOGY (2020)
Host Immune Defense upon Fungal Infections with Mucorales: Pathogen-Immune Cell Interactions as Drivers of Inflammatory Responses
Dolly E. Montano et al.
JOURNAL OF FUNGI (2020)
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2019)
Challenges in the diagnosis and treatment of mucormycosis
A. Skiada et al.
MEDICAL MYCOLOGY (2018)
Understanding Mucor circinelloides pathogenesis by comparative genomics and phenotypical studies
Loida Lopez-Fernandez et al.
VIRULENCE (2018)
A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae
Paul Castillo et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis
Teclegiorgis Gebremariam et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis
Teclegiorgis Gebremariam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis
Teclegiorgis Gebremariam et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens et al.
LANCET (2016)
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Francisco M. Marty et al.
LANCET INFECTIOUS DISEASES (2016)
Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions
Kirti V. Sawant et al.
SCIENTIFIC REPORTS (2016)
CotH3 mediates fungal invasion of host cells during mucormycosis
Teclegiorgis Gebremariam et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
NIH plans to enhance reproducibility
Francis S. Collins et al.
NATURE (2014)
NIH to balance sex in cell and animal studies
Janine A. Clayton et al.
NATURE (2014)
Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis
Guanpingsheng y Luo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Characterization of the Cellular Immune Responses to Rhizopus oryzae With Potential Impact on Immunotherapeutic Strategies in Hematopoietic Stem Cell Transplantation
Stanislaw Schmidt et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007
A. Skiada et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Experimental murine paracoccidioidomycosis: relationship among the dissemination of the infection, humoral and cellular immune responses
L. M. SINGER-VERMES et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
CCL5 as an adjuvant for cancer immunotherapy
Natalia Lapteva et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Immunological Basis for the Gender Differences in Murine Paracoccidioides brasiliensis Infection
Camila Figueiredo Pinzan et al.
PLOS ONE (2010)
Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis
Ashraf S. Ibrahim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae
M. Mar Rodriguez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1
Thomas T. Murooka et al.
BLOOD (2008)
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
Oliver A. Cornely et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
Andrew J. Ullmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Novel perspectives on mucormycosis: Pathophysiology, presentation, and management
B Spellberg et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important Zygomycetes
C Gil-Lamaignere et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Caspofungin inhibits rhizopus oryzae 1,3-β-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis
AS Ibrahim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Epidemiology and outcome of zygomycosis: A review of 929 reported cases
MM Roden et al.
CLINICAL INFECTIOUS DISEASES (2005)
Improved outcome of zygomycosis in patients with hematological diseases?
B Gleissner et al.
LEUKEMIA & LYMPHOMA (2004)
Cross-talk in the innate immune system: Neutrophils instruct recruitment and activation of dendritic cells during microbial infection
S Bennouna et al.
JOURNAL OF IMMUNOLOGY (2003)
Respiratory syncytial virus-induced CCL5/RANTES contributes to exacerbation of allergic airway inflammation
AE John et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
R Herbrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model
QN Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
